Scientific Presentations at Society Meetings

Academy of Managed Care Pharmacy
Ballantyne C, Bhatt D, Bress A, Brinton E, Dolman S, King J, et al. Cost-effectiveness of icosapent ethyl in REDUCE-IT. Accepted abstract posted on-line due to 2020 virtual-only meeting.

Hilleman D, Teply R, Packard K. Knowledge, perceptions, and patterns of fish oil use in cardiac patients [abstract I16]. J Manag Care Spec Pharm. 2018;24(4 suppl a):S71.

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. J Manag Care Spec Pharm. 2018;24(4 suppl a):S70-S71.

American Academy of Family Physician
Crandell JR. Reductions in low-density lipoprotein cholesterol and particle concentration and improvements in other parameters of dyslipidemia in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk following switch from EPA+DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl). Presented at: The American Academy of Family Physicians conference

American Association of Clinical Endocrinologists
Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides (≥150 mg/dL) and diabetes mellitus are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis [abstract 403]. Endocr Pract. 2018;24(suppl 1):96-97.

American College of Cardiology
DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the American College of Cardiology 2020 annual meeting (virtual).

Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. EMJ. 2020;5:29-36.

Leatherman S, Ferguson RE, Hau C, Granowitz C, Harrington K, Philip S, Toth P, Bhatt D, Boden WE.Residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides across the cardiovascular risk spectrum [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1980.

Wong ND, Fan W, Toth P, Granowitz C, Philip S. REDUCE-IT eligibility and preventable first and total cardiovascular events in the US population: an analysis of the National Health and Nutrition Examination Survey (NHANES) [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1954.

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Birudaraju D, Cherukuri L, Golub I, Rezvanizadeh V, Dailing C, Flores F, Hamal S, Roy SK, Nelson J, Budoff MJ. Association of HDL subclasses with baseline coronary plaque burden by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1624

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Rezvanizadeh V, Golub I, Birudaraju D, Cherukuri L, Hamal S, Dailing C, Flores F, Roy SK, Nelson J, Budoff MJ. Association of inflammatory markers with baseline coronary plaque volumes by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 10:1720. 

Weintraub WS, Bhatt D, Zhang Z, Zhang C, Sarahfaye D, Boden WE, Steg PG, Miller M, Brinton E, King J, Bress A, Jacobson T, Tardiff JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl in US REDUCE-IT patients [abstract]. J Am Coll Cardiol. 2020;75(11 suppl 1):1914.

Mason RP, Sherratt SCR. Eicosapentaenoic acid inhibits oxidation of very large density lipoproteins (VLDL) in a dose-dependent manner over time as compared to docosahexaenoic acid in vitro [abstract]. J Am Coll Cardiol. 2020;75(11 suppl 1):2238.

Mason RP, Sherratt SCR. Eicosapentaenoic acid inhibits high density lipoprotein (HDL) oxidation in a synergistic manner in combination with atorvastatin in vitro [abstract]. J Am Coll Cardiol. 2020;75(11 suppl 1):2259.

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the annual meeting of the American College of Cardiology, March 16-18, 2019, New Orleans, Louisiana.

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

Wong ND, Fan W, Philip S, Granowitz C, Toth P. Burden of atherosclerotic cardiovascular disease risk in persons with elevated triglyceride levels according to statin use [abstract]. J Am Coll Cardiol. 2019;73:1763. 

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Triglycerides ≥150 mg/dL associated with greater risk of cardiovascular events, costs and resource utilization in high-risk statin-treated patients with controlled low-density lipoprotein cholesterol: a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1444.

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

Nichols GA, Philip S, Granowitz C, Reynolds K, Fazio S. Increased medical care costs in patients with statin-controlled low-density lipoprotein cholesterol and residual hypertriglyceridemia [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1723.

Mason RP, Jacob RF, Dawoud H, Wagner MR, Mahmud FJ, Sherratt SCR, Malinski T. Eicosapentaenoic acid and atorvastatin active metabolite, alone or in combination, reversed glucose- and oxidized LDL-induced endothelial dysfunction measured ex vivo in rats [abstract]. J Am Coll Cardiol. 2016;67(suppl):2320.

Mason RP, Jacob R, Corbalan JJ, Malinski T. Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents [abstract]. J Am Coll Cardiol. 2015;65:A2139.

Mason RP, Jacob RF, Dawoud H, Alhumaid H, Mahmud FJ, Sherratt SCR, Malinski T. Eicosapentaenoic acid, but not other TG-lowering agents, reversed hyperglycemia-induced rat endothelial cell dysfunction and enhanced the benefits of atorvastatin active metabolite ex vivo [abstract 2178-PUB]. Diabetes. 2016;65(suppl 1):A554.

American Diabetes Association – Freely accessible
Bhatt DL, Brinton EA, Miller M,et al. Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES. Diabetes. 2020;69(Supplement 1):4-LB.

Toth PP, Philip S, Hull M, Granowitz CB. Long-term statin persistence is poor among high-risk patients with baseline diabetes: a real-world administrative claims analysis. Diabetes. 2019;68(suppl 1):616P.

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trial. Diabetes. 2019;68(suppl 1):1472P.

Sherratt S, Mason RP. Eicosapentaenoic acid (EPA) inhibits human HDL oxidation in a concentration-dependent manner at a pharmacologic dose in vitro. Diabetes. 2019;68(suppl 1):612P.

Toth PP, Granowitz CB, Hull M, Philip S. Diabetes mellitus and high triglycerides are significant predictors of major cardiovascular events and increased health care costs and resource utilization – a real-world analysis of high-risk statin-treated patients [abstract]. Diabetes. 2018;67(suppl 1):416P.

Nichols G, Philip S, Granowitz CB, Reynolds K, Fazio S. Increased cardiovascular risk in patients with diabetes, statin-controlled LDL cholesterol, and residual hypertriglyceridemia [abstract]. Diabetes. 2018;67(suppl 1):1485P.

Fan W, Philip S, Granowitz CB, Toth PP, Wong ND. Prevalence and predictors of residual hypertriglyceridemia according to statin use in U.S. adults with diabetes [abstract]. Diabetes. 2018;67(suppl 1):332OR.

Brinton EA, Guyton JR, Ballantyne CM, Philip S, Doyle Jr, RT, Juliano RA, Mosca L. Icosapent ethyl in statin-treated women with persistent high triglycerides and diabetes mellitus: ANCHOR study subanalysis [abstract 633-P] Diabetes. 2017;66(suppl 1):A165.

Mason RP, Sherratt SCR, Dawoud H, Jacob RF, Alhumaid H, Mahmud FJ, Malinski T. Eicosapentaenoic acid reduces small dense low-density lipoprotein oxidation and human endothelial dysfunction in vitro in a manner distinct from docosahexaenoic acid [abstract 2302-PUB] Diabetes. 2017;66(suppl 1):A601.

Brinton EA, Ballantyne CM, Bays HE, Cromwell W, Otvos J, Philip S, Doyle RT, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides: ANCHOR patients with diabetes mellitus [abstract 1173-P]. Diabetes. 2016;65(suppl 1):A308.

Mason RP, Jacob RF. Eicosapentaenoic acid (EPA) reduces glucose-induced small dense low-density lipoprotein oxidation in vitro in a manner distinct from other triglyceride-lowering agents and vitamin E [abstract 705-P]. Diabetes. 2015;64(suppl 1):A178-9. 

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract 629-P]. Diabetes. 2012;61(suppl 1):A159-60.

American Heart Association
Budoff MJ, Muhlestein JB, Bhatt DL, Le VT, May HT, Shaikh K, Shekar C, Kinninger A, Lakshmanan S, Roy S, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy (EVAPORATE study) [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

Weintraub WS, Bhatt DL, Zhang Z, Dolman SF, Zhang C, Boden II WE, Bress AP, King JB, Steg PG, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl in REDUCE-IT [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

Melendez GC, Medina-Hernandez D, Pflum AW, Xu V, Herrington DM. Purified eicosapentaenoic acid ameliorates cardiac fibrosis and tissue inflammation in spontaneously hypertensive rats [abstract]. Circulation. 2019;140(suppl 1):A13892.

Spyropoulos J, Boutsalis G, Anderson D. Improving appropriate use of omega-3 fatty acids in primary care: success of online CME [abstract]. Circulation. 2019;140(suppl 1):A16351.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum S, Doyle R, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM. REDUCE-IT USA: results from the 3,146 patients drandomized in the United States [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

Sherratt SC, Mason RP. Contrasting effects of eicosapentaenoic and arachidonic acid on membrane cholesterol crystal formation under hyperglycemic conditions [abstract]. Circulation. 2019;140(suppl 1):A13936.

Wong ND, Fan W, Philip S, Toth PP, Granowitz C. Many statin treated persons with borderline triglyceride levels are at risk of ASCVD [abstract]. Circulation. 2019;140(suppl 1):A13771.

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif, JC, Ballantyne CM. The primary results of the REDUCE-IT trial [abstract 19515]. Circulation. 2018;138:e752-e753.

Sherratt SC, Mason RP. Eicosapentaenoic acid, unlike other omega-3 fatty acids, inhibits membrane cholesterol crystalline domains under conditions of hyperglycemia [abstract]. Circ Res. 2019;125(suppl 1):A784.

Toth PP, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline ASCVD or revascularization: a real-world administrative claims analysis [abstract]. Circulation. 2018;138(suppl 1):A14290.

Pflum AW, Robinson KC, Bi J, Xu V, Herrington DM, Melendez GC. Beneficial effects of purified eicosapentaenoic acid on myocardial fibrosis and diastolic cardiac function in spontaneously hypertensive rats [abstract]. Circulation. 2018;139(suppl 1):A13176.

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients in a real-world administrative claims analysis [abstract]. Circulation. 2017;136(suppl 1):A15786.

Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides increase cardiovascular events, medical costs, and resource utilization in a real-world analysis of statin-treated patients with high cardiovascular risk and well-controlled low-density lipoprotein cholesterol [abstract]. Circulation. 2017;136(suppl 1):A15187.

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Chowdhury S, Doyle RT, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated women with persistent high triglycerides: results from the ANCHOR study [abstract 15922]. Circulation. 2016;134(suppl 1):A15922

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract]. Circulation. 2014;130:A16803. 

Bays H, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. High-sensitivity C-reactive protein effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) with and without stable statin therapy in hypertriglyceridemic patients with metabolic syndrome [abstract]. Circulation. 2013;128:A19342.

Bays H, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. High-sensitivity C-reactive protein effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) with and without stable statin therapy in hypertriglyceridemic patients with metabolic syndrome [abstract]. Circulation. 2013;128:A19342.

Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101 lowers triglycerides, atherogenic lipoprotein, phospholipase A2, and high-sensitivity C-reactive protein levels in patients with high triglycerides and on background statin therapy (the ANCHOR study) [abstract]. Circulation. 2011;124:A15071.

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Effects of AMR101, a pure ethyl eicosapentaenoic acid omega-3 fatty acid, on lipoprotein particle concentration and size in patients with very high triglycerides (the MARINE study) [abstract]. Circulation. 2011;124:A14232.

American Heart Association/American Stroke Association Basic Cardiovascular Sciences
Sherratt SC, Mason RP. Eicosapentaenoic acid, unlike other omega-3 fatty acids, inhibits membrane cholesterol crystalline domains under conditions of hyperglycemia [abstract]. Circ Res. 2019;125(suppl 1):A784.

Sherratt SCR, Mason RP. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids. 2018;212:73-79.
Free:

American Society for Preventive Cardiology
Peterson BE, Bhatt DL, Steg G, et al. Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl:  insights from REDUCE-IT REVASC. Presented at the American Society for Preventive Cardiology 2020 annual meeting (virtual).

Bays HE, Ballantyne CM, Philip S, Juliano RA, Doyle RT, Granowitz CG.
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.
Presented at: The American Society for Preventive Cardiology, July 27-29, 2018, Santa Ana Pueblo, NM. 

Bays HE, Ballantyne CM, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study [abstract]. Eur Heart J. 2011;32(suppl 1):342.

European Atherosclerosis Society
Mason RP, Sherratt SCR, Malinski T. Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitro. Presented at: The European Atherosclerosis Society Congress, May 5-8, 2018, Lisbon, Portugal.

Mason R, Sherratt S. Eicosapentaenoic Acid (EPA) Inhibits Human Low-Density Lipoprotein Oxidation in a Concentration- And Time-Dependent Manner at Pharmacologic Doses In Vitro [abstract EAS19-0568]. Atherosclerosis. 2019; in press.

Konishi T. Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging. Clin Cardiol. 2019;42(6):618-628.

Nordestgaard BG. Triglycerides, lesson from genetics. EMJ Cardiol. 2019;7:57-59.

Bhatt DL. Does high-dose fish oil reduce cardiovascular events via triglycerides? EMJ Cardiol. 2019;7:59-60.

Gitt AK. Prevalence of hypertriglyceridaemia in statin treated very high-risk patients who might benefit from treatment with icosapent ethyl for secondary prevention in clinical practice–results of DYSIS. EMJ Cardiol. 2019;7:61-62.

Toth PP, Philip S, Hull M, Liassou D, Anderson A, Granowitz C. Triglycerides 150 mg/dL and above are associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a real-world analysis [abstract P739]. Eur Heart J. 2018;39(suppl):119.

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT, Soni PN, Juliano R. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract P1679]. Eur Heart J. 2015;36(suppl 1):287. 

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract]. Eur Heart J. 2012;33(suppl 1):280.

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE trial) [abstract]. Eur Heart J. 2011;32(suppl 1):510-511.

Gordon Conference on Atherosclerosis
Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Eicosapentaenoic acid exposure lowers triglycerides without raising LDL-C by slowing TRL production and hastening LDL clearance in patients with residual triglyceridemia. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Kern Lipid Conference
Abstracts are not published – approved to post to Amarin’s website
Juliano RA, Braeckman RA, Manku MS, Ballantyne CM, Doyle RT Jr, Soni PN, Stirtan WG. Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Presented at: The Kern Lipid Conference, August 3-4, 2015, Vail, Colorado.

PI|LIFESTYLE (Epidemiology and Prevention | Lifestyle and Cardiometabolic Health)
Robert RC, Liu L, Tsai MY, O'Connell TD, Shearer GC. Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis. Circulation . 2018;137:A026.

International Society for the Study of Fatty Acids and Lipids
Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of small dense LDL in a manner distinct from related fatty acids in vitro [poster]. Presented at: The Congress of the International Society for the Study of Fatty Acids and Lipids, Las Vegas, Nevada, May 27-31, 2018.

International Society for Pharmacoeconomics and Outcomes Research
Nichols GA, Reynolds K, Philip S, Granowitz C, Fazio S. The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials [abstract PRM9]. Value Health. 2017;20:A312.

Nyandege A, Burudpakdee C, Philip S. Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients [abstract PRM20]. Value Health. 2014;17:A546.

National Lipid Association
Lee A, Kinninger A, Jayawardena E, Shekar C, Cherukuri L, Dailing C, Hamal S, Flores F, Budoff M, Nelson J. Relationship between lipid levels and coronary atherosclerotic plaque scores by coronary computed tomography angiography (CTA) in subjects with elevated triglycerides. J Clin Lipidol. 2019.

Case BC, Bress A, Kolm P, Philip S, Herrick J, Granowitz C, Toth P, Fan W, Wong N, Hull M, Weintraub W. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. J Clin Lipidol. 2019.

Philip S, Fan W, Granowitz C, Toth P, Wong N. Prevalence of US adults with triglycerides ≥135 mg/dL: NHANES 2007-2014. J Clin Lipidol. 2019.

Cherukuri L, Shekar C, Kinninger A, Birudaraju D, Jayawardena E, Hamal S, Flores F, Tayek J, Roy S, Budoff M, Nelson J. Association between lipids and coronary atherosclerotic plaque characteristics. J Clin Lipidol. 2019.

Sherratt S, Mason R. Eicosapentaenoic acid, unlike arachidonic acid, maintains normal membrane structure and cholesterol distribution under conditions of hyperglycemia. J Clin Lipidol. 2019.

Cherukuri L, Shekar C, Kinninger A, Birudaraju D, Hamal S, Flores F, Tayek J, Roy S, Budoff M, Nelson J, Johanis A. Comparison of atherosclerotic plaque characteristics among normal and high triglycerides (TGs) patients. J Clin Lipidol. 2019; epub ahead of print.
https://www.lipidjournal.com/article/S1933-2874(19)30118-7/fulltext

Hilleman D, Teply R, Packard K. Knowledge, perceptions, and patterns of fish oil use in cardiac patients [abstract 165]. J Clin Lipidol. 2018;12(2):552-553.

Nelson J, He L, Gill R, Dansinger M. Plasma EPA (eicosapentaenoic acid)/AA (arachidonic acid) ratio in patients with stage 5 chronic kidney disease: a novel, treatable target? [abstract 183]. J Clin Lipidol. 2018;12(2):553-554.

Nichols G, Granowitz C, Reynolds K, Philip S, Fazio S. The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials [abstract 138]. J Clin Lipidol. 2017;11:796-797.

National Kidney Foundation
Szerlip HM, Vijay K, Ballantyne CM, Bays HE, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and diabetes mellitus [abstract 295]. Am J Kidney Dis.2018;71(4):589.

Vijay K, Szerlip HM, Ballantyne CM, Nelson JR, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and elevated high-sensitivity C-reactive protein =2.0 mg/L [abstract 317]. Am J Kidney Dis. 2018;71(4):594-595.

Obesity Society
Kedia AW, Lynch E. Omega-3 fatty acid treatment in an obese patient with hypertension and persistently elevated triglycerides despite statin therapy: reductions in triglycerides and low-density lipoprotein cholesterol and improvements in other lipid parameters following switch from omega-3 fatty acid ethyl esters to icosapent ethyl [abstract]. Presented at: the Annual Obesity Week meeting, November 2-7, 2015, Los Angeles, California.
Available online at: Page S154